The drug GW016 shows great promise. Its full designation is GW572016.
Below is a link to all of the clinical trials currently underway for this drug. Phase III clinical trials test the drug's effectiveness using many patients.
I spoke with representatives of GSK in San Antonio. They were very excited about its prospects.
Hugs
Christine
|